NewCelX

Company Overview

Snapshot

Founded in October 2008 by Michel Revel, NewCelX operates with 11–50 employees. The company has raised $45.35M across 9 funding rounds from 11 investors. In October 2025, NewCelX completed a merger with NLS Pharmaceutics Ltd. and subsequently went public on NASDAQ.

Business overview

NewCelX is a biotechnology company focused on developing advanced cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company leverages an integrated platform that combines sophisticated stem-cell technologies with neuroscience expertise. Its core products, IsletRx and AstroRx, target conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes, serving the pharmaceuticals and life sciences markets within the Health Tech & Life Sciences sector.

Strategic signal

In November 2025, NewCelX announced a strategic roadmap update following its merger with NLS Pharmaceutics Ltd., signaling a clear direction for accelerated execution, particularly for its diabetes drug program in 2026. This indicates a strong post-merger integration and a focused approach to advancing its therapeutic pipeline, providing investors with a forward-looking view of the company's operational priorities and growth trajectory.

Company Intelligence Q&A

What was a significant recent corporate development for NewCelX?

In October 2025, NewCelX completed a reverse merger with NLS Pharmaceutics Ltd., leading to its public listing on NASDAQ. This transaction was a pivotal step for the company's market presence and access to capital.

What was the outcome of the shareholder vote regarding the merger?

In September 2025, NLS Pharmaceutics shareholders approved the merger with Kadimastem (now NewCelX) and related proposals at an Extraordinary General Meeting, paving the way for the combined entity.

Did NewCelX receive any recent grants?

In July 2025, the BIRD Foundation approved an additional milestone payment to Kadimastem (now NewCelX) and iTolerance for the continued co-development of their Type 1 Diabetes cell therapy, highlighting ongoing support for the ITOL-102 program.

What recent patent approval did NewCelX receive?

In September 2025, NewCelX (formerly Kadimastem) and NLS Pharmaceutics announced a Hong Kong patent covering cell-selection and enrichment technology for IsletRx, their diabetes treatment.

What is the company's current strategic focus following the merger?

In November 2025, NewCelX provided a business and strategic roadmap update following the closing of the merger with NLS Pharmaceutics Ltd., outlining its plans for advancing its cell-based and small-molecule therapies.